Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“Birds of the Phase 1 clinical trial feather flock together Harvard Club, Boston style.
TARGETS25 brings the NCI, EORTC, AACR crew under one roof to chase tomorrow’s targets today.
Early-drug development never looked so sharp.”
More posts featuring Early-drug development.